Pragma Bio is a tech-enabled therapeutics company creating the first-of-its-kind-map of chemicals designed by nature, housed in humans, and linked to immune-related health outcomes. Pragma Bio is forging into uncharted territory, leveraging the most advanced technologies in machine learning and synthetic biology to scale intelligent discovery with iterative biomanufacturing in the pursuit of novel enzymes and their respective novel chemistries with strong biological signals and desirable therapeutic properties. Pragma Bio is dedicated to developing innovative solutions to bring life-changing medicines to patients through internal efforts and trusted partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/23/23 | $10,000,000 | Venture |
CJ Investment Merck Global Health Innovation Fund The Venture Collective  Viking Global Investors | undisclosed |
